2015 rate card print5e3548d14dcea9ad4884-3d60fc0fa5878c65be6ab1e2048633f4.r92. print rates 1.eye: th
Post on 25-Jul-2020
Embed Size (px)
2015 Rate Card Print
RATES 1. Black-and-White rates:
Frequency 1x 6x 12x 18x 24x 36x 48x 60x 72x 96x 108x
King Page $5,660 $5,415 $5,270 $5,145 $5,045 $4,965 $4,945 $4,930 $4,895 $4,675 $4,650
3/4 Page 4,840 4,500 4,315 4,280 4,215 4,205 4,165 4,150 4,140 4,105 4,080
Island/Half Page 3,980 3,815 3,670 3,650 3,630 3,565 3,545 3,495 3,485 3,340 3,310
1/3 Page 2,155 1,890 1,785 1,760 1,710 1,705 1,700 1,685 1,640 1,605 1,570
1/4 Page 1,830 1,705 1,690 1,670 1,625 1,600 1,575 1,570 1,530 1,510 1,470
1/8 Page 1,335 1,265 1,225 1,215 1,200 1,145 1,135 1,110 1,100 1,080 1,035
Color: In addition to earned black-and-white rates.
Charge per color per page or fraction
Standard color $1,230
Matched color 1,380
Metallic color 1,770
Four color 2,220
Four color + PMS 3,600
Four color + Metallic 3,990
2. Rates: a) Earned rates are given to advertisers (parent
company and its subsidiaries) based on the total number of pages within a 12-month period. A spread counts as two pages regardless of its size (King-size or A-size).
b) Agency commission: Fifteen percent gross billings on space, color, cover, and preferred position charges.
c) Cash discount: Two percent if paid within ten days of invoice date. No discount allowed after this period.
3. Bleed: No charge
4. Covers, Special Positions: a) Covers:
Second cover: Earned b/w rate plus 25%. Color additional. Third cover: Earned b/w rate plus 15%. Color additional. Fourth cover: Earned b/w rate plus 50%. Color additional.
b) Special Positions: Contact your sales representative for more details.
5. Online Advertising Rates: Please contact your sales representative for more information.
6. Recruitment/Classified Rates: Please contact your regional sales representative at 800-257-8290.
Effective Rate Date: January 2015 for all advertisers.
EXCLUSIVES COVER STORY
Cover story continues on page 10
A SLACK Incorporated® publication
OCULAR SURGERY NEWS
Point-of-care tests for ocular surface disease gaining acceptance as diagnostic tools Ocular surface disease has various causes, and in- offi ce testing is one means to defi ne those causes. Red eye: Th ere is a test for that. Meibomian gland dys- function: Th ere is a test for that. Allergy: Th ere is a test for that. Dry eye: Th ere is a test for that — more than one.
Point-of-care testing (POCT) is a growing area in ophthalmology in which clinicians obtain immedi- ate results that enhance the accuracy of a diagnosis or help rule one out during one clinic visit. Th e most common testing done in an ophthalmologist’s of- fi ce is for ocular surface disease, which encompasses three primary areas: dry eye, meibomian gland dys- function and ocular allergy.
Th e advantages of these in-offi ce tools are speed and simplicity; the disadvantage may be lack of rev- enue, according to OSN Healio.com/Ophthalmology Board Member William B. Trattler, MD.
“[POCT] is very simple to implement in your of- fi ce,” Trattler said. “It probably won’t generate a lot of income, but it really helps us hone the diagnosis to better care for our patients.”
“We are just in the beginning of the general
Point-of-care tests for ocular surface disease are technically easy for offi ce staff to perform and are comfortably easy for patients to endure, according to Darrell E. White, MD.
Pre-Descemet’s endothelial keratoplasty combines advantages of DSAEK, DMEK
The PDEK graft allows easy intraoperative handling because it is not as fl imsy as Descemet’s membrane alone, and PDEK can use donor eyes of any age. 33
All eye care practitioners should utilize point-of- care testing 6
NEWS YOU CAN USE FROM UPMC EYE CENTER
Nonsurgical option available for long-standing or sensory strabismus in adults With Botox, improvements in the position of the eye can be seen even after the initial 3-month paresis has worn off . 7
IN THE JOURNALS
Intravitreal ranibizumab associated with subfoveal choroidal thinning in idiopathic disease Intravitreal ranibizumab therapy was associated with thinning of the subfoveal choroid in patients treated for unilateral idiopathic subfoveal choroidal neovascularization. 23
Meeting coverage starts on page 14
Kiawah Eye 2014 May 29-31
Meeting News Coverage
Ten-point scorecard can assess administrator prowess The success of your administrator has a direct eff ect on the success of your practice. 25
Surgical Maneuvers: Early results of stab incision glaucoma surgery promising The technique involves the creation of a compromised leaking corneoscleral tunnel with minimal to no conjunctival dissection. 4
GAITHERSBURG, Md. — Amid concerns about safety and study methodology, the U.S. Food and Drug Administration’s Ophthal- mic Devices Panel of the Medical Devices Advisory Committee voted recently on three questions concerning the Kamra inlay.
Although more panel members voted “no” on a question of the device’s safety, a majority voted “yes” on efficacy and a slim majority voted “yes” on whether the de-
vice’s benefits outweigh the risks. Th e Kamra inlay (AcuFocus) is indicated
for the improvement of near and intermedi- ate vision in presbyopic patients. Th e inlay is placed intrastromally in the cornea on the visual axis through a femtosecond laser- created pocket using a spot/line separation of 6 μm × 6 μm or less. Placement of the in- lay should be at a depth of 180 μm or greater.
“Th e Kamra inlay represents more than a
decade of research, development and clinical evaluation, and we appreciated the opportu- nity to present the Kamra data back to the Ophthalmic Devices Advisory Panel,” Nick Tarantino, MD, chief clinical and regulatory offi cer for AcuFocus, said in a company press release.
On the question of the implant’s safety in patients who meet the criteria specifi ed in the
FDA panel continued on page 3
Volume 32 • Number 13
JULY 10, 2014
FDA panel affi rms Kamra inlay’s effi cacy and benefi ts, votes ‘no’ on safety
OSN Italy 2014 May 23-24
AOS American Ophthalmological Society May 15-18
OSNUS07A14pgs1,10-13.indd 1 6/18/2014 3:51:21 PM
Advertising Office: SLACK Incorporated
Patrick Duffey Vice President, Sales & Marketing email@example.com, ext. 262
Scott Wright Global Sales Director, Eye Care Group firstname.lastname@example.org, ext. 363
Jenna Gentile Senior Account Manager email@example.com, ext. 359
Megan Wadsworth Sales Administrator firstname.lastname@example.org, ext. 451
6900 Grove Road Thorofare, NJ 08086-9447 856-848-1000 • 800-257-8290 Fax 856-848-6091
Click to view full circulation info
mailto:swright%40slackinc.com?subject= mailto:jgentile%40slackinc.com?subject= mailto:rfacenda%40slackinc.com?subject= http://9086bc9fa54ef61da87b-df9d574313511ea4f6ce8fbe46fddf8c.r4.cf1.rackcdn.com/BPA_OSN_July_2013.pdf
DISCOunTS 1. Combined Earned Frequency: All insertions of a parent company and
its subsidiaries are combined to determine the earned rate. Advertisers may combine space units run in all SLACK publications to achieve maximum rate frequency.
2. Global Continuity Incentive: Advertisements for an individual product are eligible for a discount based upon the number of insertions placed in SLACK publishing’s eye care newspapers (all global editions of Ocular Surgery NewS plus Primary care OPtOmetry NewS). Insertions do not need to be consecutive. This program may not be combined with the Comprehensive Marketing Incentive. a) 3-6 insertions: 10% off b) 7-12 insertions: 15% off c) 13+ insertions: 20% off
3. Comprehensive Marketing Incentive: Advertisers may be eligible for a customized incentive program based upon a total 2015 investment in promotional, marketing and educational services provided through all global print and online editions of SLACK publishing’s eye care newspapers Ocular Surgery NewS and Primary care OPtOmetry NewS and/or associated live non-CME educational events. Contact your sales representative for details.
4. SLACK Corporate Discount: Take advantage of SLACK’s advertising, custom publishing, event management and other marketing services in 2015 and earn valuable discounts in 2016. Spend levels achieved in the year 2015 will determine your Corporate Discount savings in 2016 based on a total net spend.
5. Online/Print Synergy Program: Advertisers who take advantage of Healio. com’s advertising options will earn credit toward their print advertising earned frequency rate. Credit towards higher earned frequency is as follows: a) 25,000 impressions count as one ad page toward earned frequency b) Each Newswire advertisement counts as one ad page toward earned
There is no cap on earned credits toward print frequency level. Online value- added does not award credit toward print earned frequency.
6. When taking advantage of more than one discount program, discounts must be taken in the following order: Gross Cost: a) Less Global Continuity Incentive or Comprehensive Marketing In